Minsheng technology’s net profit will increase by 29% in 2020, and the sales revenue of its subsidiary Tianxu pharmaceutical will increase substantially



On April 26, Minsheng Technology (832996) recently released its 2020 annual report. During the reporting period, the company achieved an operating revenue of 677645601.65 yuan, up 30.41% year on year; The net profit attributable to the shareholders of the listed company was 106498475.97 yuan, up 29% year on year.


民生科技2020年净利增长29% 子公司天戌药业销售收入大幅增长

During the reporting period, the net cash flow from operating activities was 91318382.72 yuan, and the net assets belonging to the shareholders of the listed company was 454104539.58 yuan by the end of 2020.

During the reporting period, the operating revenue was 677645601.65 yuan, an increase of 30.41% over the same period of last year, and the operating revenue of this period increased by 158.03 million yuan over the previous period. This was mainly due to the substantial increase of 174.81 million yuan in the sales revenue of the subsidiary Tianxu pharmaceutical.

The net profit was 106498475.97 yuan, an increase of 29% over the same period of last year. The net profit of this period increased by 23.94 million yuan over the previous period. This is mainly due to the growth of sales revenue and net profit.

According to the data of digbei.com, Minsheng technology is a manufacturer in the fine chemical industry. Its main business includes R & D, production and sales of various pharmaceutical and pesticide intermediates. It has patented technology, core technology team and import and export trade qualification, providing high-quality high-tech products for API, pharmaceutical and pesticide intermediates manufacturers at home and abroad.

 


发表评论

邮箱地址不会被公开。 必填项已用*标注